DR Horton Inc (DHI) Investor Brief

DR Horton Inc is currently being reviewed as a consumer cyclical company. Its market capitalization sits around 39.9B USD. The latest EBIT margin is about 13.8%. The indicated dividend yield is roughly 1.2%.

The score mix looks transitional rather than settled, with growth score at about 2.6 out of 4 and maturity score around 2.5 out of 4, which often means the business is still proving what kind of long-term profile it wants to become. The execution-quality backdrop is fair, but not so strong that it can carry a weaker business profile on its own. The cleaner support currently comes from Liquidity Position and Cashflow Strength, and the resilience score itself sits around 3.1 out of 5.

DR Horton Inc is currently assessed as halal compliant. It operates in a Halal-compliant industry. The predictive one-year Halal overlay presently classifies DR Horton Inc as expected to remain compliant within the coming year.

On the financial screen, interest income is around 0.00% versus the AAOIFI threshold of 5.00%, debt is around 11.48% versus the AAOIFI threshold of 30.00%, securities is around 6.56% versus the AAOIFI threshold of 30.00%. These thresholds follow AAOIFI-based screening standards used in purepofo’s methodology. Taken together, these ratio checks suggest the financial screen is being passed with visible room rather than by only a narrow margin.

DR Horton, Inc. is a home construction company incorporated in Delaware and headquartered in Arlington, Texas. Horton has operations in 126 markets in 36 states across the United States and is engaged in the construction and sale of high-quality homes through its diverse product portfolio with sales prices generally ranging from $200,000 to over $1,000,000.

The score mix looks transitional rather than settled, with growth score at about 2.6 out of 4 and maturity score around 2.5 out of 4, which often means the business is still proving what kind of long-term profile it wants to become.

Investors can see the support most clearly in Income Growth, Valuation Momentum, Profit Stability and Dividend Trend, but they should not ignore Profitability Trend and Risk-Adjusted Returns as remaining constraints.

Return data matters most when it shows not only the outcome, but whether momentum is strengthening, cooling, or staying uneven. The latest 1-year ROI is -18.2%. The trailing 3-year compounded ROI is +22.2%. The longer 5-year compounded ROI is +57.9%.

Across the horizons, the main takeaway is that the stock’s strongest evidence sits in the longer compounding record. The Sharpe ratio is less flattering, which means the return record has come with a heavier volatility cost than stronger peers usually show.

Street targets currently imply a move from roughly 142.75 USD to 162.92 USD, or about +14% from 14 analyst estimates. It is better used as a rough expectation marker than as a promise.

The available signals point to a rewarding longer-term return record, income growth and valuation momentum.

The stock still asks investors to keep an eye on product concentration and trade-policy sensitivity.

Stepping back from the details, DR Horton Inc remains an execution-led candidate: growth at 2.6 out of 4 and maturity at 2.5 out of 4, which still describes a transitional business profile, so a stronger operating record would make the case easier to underwrite.